The postdoctoral researcher at the Johns Hopkins Multiple Sclerosis Center shared his perspective on the use of spinal cord atrophy in clinical practice to measure disease progression in MS and how it might become more accessible. [WATCH TIME: 4 minutes]
Theresa Sevilis, DO, writes on picking a career path in medicine as a woman, and how deciding to jump ship from a traditional path was among the best decisions she's made.
Mary Schroth, MD, and Jacqueline Glascock, PhD, of Cure SMA, share their perspectives on the upcoming annual meeting.
Looking to the future of multiple sclerosis care, the panel of thought leaders pose important questions that remain to be answered in the research and treatment of multiple sclerosis.
In light of Tuberous Sclerosis Complex (TSC) Awareness Month throughout May, Kari Rosbeck, president and CEO, TSC Alliance, highlights what has been done to advance TSC research and how the organization is improving the diagnosis journey, access to care, and support for families.
The chief medical officer of Prime PD, a new digital wellness studio for patients with Parkinson disease, detailed future initiatives for the platform. [WATCH TIME: 4 minutes]
The clinical assistant professor of neurology in the Comprehensive Epilepsy Center at NYU Langone Health gives recommendations for clinical care on prescribed antiseizure medication and RNA therapy. [WATCH TIME: 5 minutes]
The director of Geriatric Psychiatry at the St Louis University School of Medicine discussed the need to improve awareness of the signs of psychiatric-related symptoms and to eliminate the stigmas associated with them. [WATCH TIME: 3 minutes]
The Medical Director of The Neuroscience Institute at UW Medicine Valley Medical Center discussed the landscape of therapy for tonic-clonic seizures and how lacosamide might fit into the paradigm.
Following her presentation at MDS 2021, the PhD candidate in epidemiology at Erasmus University Medical Center discussed highlights from this year’s virtual congress. [WATCH TIME: 2 minutes]
The assistant director of the Allegheny Headache Center provided insight on how the center utilizes its headache registry to construct treatment plans, along with identifying questions that still need answers. [WATCH TIME: 3 minutes]
The chief of emergency medical services at Jefferson Health spoke about the operation of the Jefferson mobile stroke unit in the field, and the impact that the onset of the COVID-19 pandemic had on launching the program. [WATCH TIME: 3 minutes]
What physicians in the community need to know about treating patients with migraine in community settings, and resources that can help locate certified headache specialists or other migraine specialists for referral.
Plagued by a long history of under- and inadequate treatment, clinicians have more options than ever to craft a personalized, effective plan for their patients.
The director of neuromuscular clinical trials at Columbia University Irving Medical Center shared her perspective on the challenges of familiarizing oneself with the influx of novel medications for neuromuscular diseases. [WATCH TIME: 3 minutes]
The chief medical officer at SanBio discussed how the investigational agent SB623 is being studied in TBI and stroke, with future planned studies in Alzheimer disease.
Panelists look ahead in the management of advanced Parkinson disease and discuss the promise of different investigational therapies.
The associate professor at Hokkaido University and investigator of STEMTRA also discussed other efforts in stroke, Alzheimer disease, and Parkinson disease.
The professor of neurology at the NYU Grossman School of Medicine provided his thoughts on the most notable strides within the multiple sclerosis field in the past year. [WATCH TIME: 3 minutes]
The Edward F. and Barbara A. Bell Endowed Chair at Cleveland Clinic discussed the complexities with identifying viable biomarkers for Parkinson disease, as well as interventions geared toward specific regions of the brain. [WATCH TIME: 4 minutes]
The assistant clinical professor at Vanderbilt University School of Medicine discussed ways of incorporating and encouraging women physicians to enter the neurology specialty. [WATCH TIME: 4 minutes]
The executive director of the Alliance for Headache Disorders Advocacy provided perspective on the preparation that goes into Headache on the Hill, and the parties involved in this process. [WATCH TIME: 5 minutes]
Following the publication of a recent article outlining the association of the use of anesthesia during surgery and cognitive decline in older adults, the assistant professor of anesthesiology at the David Geffen School of Medicine, UCLA, spoke on the need to assess risk factors. [WATCH TIME: 5 minutes]
The senior vice president and chief scientific officer of the Parkinson’s Foundation discussed the potential for new therapies that target genetically mutated forms of Parkinson disease. [WATCH TIME: 3 minutes]
The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.
Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.
Stephen Krieger, MD; Daniel Bandari, MD, MS; Bruce Hughes, MD; Mitzi Williams, MD; and Heidi Crayton, MD, provide key takeaways for the treatment of patients with multiple sclerosis.
The president and CEO, as well as the executive vice president and chief research officer, of MDA, together offered an in-depth overview of what to expect from the 2023 MDA Conference, which will be held from March 19-22, 2023, in Dallas, Texas. [WATCH TIME: 12 minutes]
The director of stem cell biology research at City of Hope spoke on the newly developed brain organoid, which has the potential to help investigators identify pathological mechanisms of Alzheimer disease.